A first-of-its-kind cancer drug has just been approved by the U.S. Food and Drug Administration for use in patients with many types of cancer, including malignant mesothelioma. The drug is manufactured by Bayer and is called larotrectinib, though it is sold under the brand name Vitrakvi. It is a genetics-based treatment that is provided based…
The post FDA Approves Genetics-Based Cancer Treatment That May Be Used in Mesothelioma Patients appeared first on Mesothelioma.net.
from Mesothelioma.net http://bit.ly/2DDhBcj
via IFTTT
FDA Approves Genetics-Based Cancer Treatment That May Be Used in Mesothelioma Patients
![FDA Approves Genetics-Based Cancer Treatment That May Be Used in Mesothelioma Patients]()
Reviewed by Unknown
on
January 28, 2019
Rating:
No comments: